Navigation Links
Riquent in Medical News

BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent

NOVATO, Calif. and SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) and La Jolla Pharmaceutical Company (Nasdaq: LJPC ) announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug ...

BioMarin Announces Second Quarter 2009 Financial Results

...8 exclude (1) stock compensation expense $34 million for 2009 and $25.3 million for 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction million in 2009 and $1.4 million associated with the Summit transaction in 2008; (3) impairment charges of $5.9 million in 2009 and $4.1 m...
Riquent in Medical Technology

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodies to Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial ...

La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced updated interim antibody reduction data for the Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). The updated analyses reinforce ...
Riquent in Biological Technology

Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile

NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that the continuation of the trial i...

BioMarin Announces First Quarter 2009 Financial Results

...arter of 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction classified as research and development expense in the first qua...lion for 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction million in 2009 and $1.4 million associated with the Summit tra...

BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results

...e* $110 to $120 Costs Associated with riquent Deal** Up to $15 Interest Income ...d development expenses associated with the riquent deal ** Represents upfront costs associated with the riquent deal to be allocated between research and ...
Other Tags
(Date:8/4/2015)... , ... August 04, 2015 , ... The goal of ... though the desire for invasive surgery to achieve this ideal is not. But minimally ... people crave without the high cost or lengthy recovery time, according to Valerie ...
(Date:8/4/2015)... ... August 04, 2015 , ... Loyola University ... that its RN to BSN and Master of Science in Nursing in ... June 2020 from the Commission on Collegiate Nursing Education (CCNE), the ...
(Date:8/4/2015)... ... ... Nathan’s Famous was recently featured on NewsWatch as part of its monthly Biz ... their industry. Andrew Tropeano, the host of NewsWatch and business expert, conducted the business ... 50% Reduced Fat All-Beef Frank variety and is celebrating summer with Nathan’s Original ...
(Date:8/4/2015)... ... August 04, 2015 , ... Please join us for the 4th ... 20th at Oneida Shores Park in Brewerton, NY. , Doris Connor was a ... at the young age of 59. Her family and friends have since become steadfast ...
(Date:8/4/2015)... ... 04, 2015 , ... IN AMERICA and the program's host, ... Depression affects millions of Americans every single year. To help people obtain a ... with the latest segment produced with the assistance of several top medical professionals. ...
Breaking Medicine News(10 mins):Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
Other Contents